<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051387</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-IS</org_study_id>
    <secondary_id>2008-008245-38</secondary_id>
    <nct_id>NCT02051387</nct_id>
  </id_info>
  <brief_title>Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study</brief_title>
  <acronym>CBD-IS</acronym>
  <official_title>Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite recent advances in the understanding and treatment of schizophrenia, this devastating&#xD;
      disease still affects one percent of world's population. Existing antipsychotics reduce&#xD;
      psychotic symptoms but are generally not very effective in treating so called negative&#xD;
      symptoms such as blunted affect and social withdrawal or cognitive disturbances due to the&#xD;
      disease. Furthermore, a significant portion of patients is refractory to all current&#xD;
      treatments. Therefore new treatment strategies are needed.&#xD;
&#xD;
      Several studies suggest a strong association between schizophrenia and the endocannabinoid&#xD;
      system. This system mediates e.g. the pro-psychotic effects of the best-known ingredient of&#xD;
      the cannabis plant - delta-tetrahydrocannabinol (Δ9-THC). While the pro-psychotic Δ9-THC is&#xD;
      known to abet the onset of schizophrenia, another, non-psychotomimetic plant ingredient -&#xD;
      cannabidiol - has recently been shown to exert antipsychotic effects similar to those of one&#xD;
      of the most effective modern antipsychotics, amisulpride, but it induced significantly less&#xD;
      side effects.&#xD;
&#xD;
      In this phase I safety study, the investigators will evaluate the pharmacokinetics,&#xD;
      pharmacoequivalence, and drug-drug interaction profile with current antipsychotics of a new&#xD;
      tablet pharmaceutical preparation of cannabidiol in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of cannabidiol</measure>
    <time_frame>up to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum antipsychotic concentration</measure>
    <time_frame>baseline and after seven days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cannabidiol capsule, 200 mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol tablet, various dosages</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Amisulpride and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Olanzapine and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Quetiapine and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Risperidone and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabidiol CR and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cannabidiol CR levels without interaction with antipsychotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol CR</intervention_name>
    <arm_group_label>Amisulpride and Cannabidiol CR</arm_group_label>
    <arm_group_label>Cannabidiol CR</arm_group_label>
    <arm_group_label>Cannabidiol CR and Placebo</arm_group_label>
    <arm_group_label>Olanzapine and Cannabidiol CR</arm_group_label>
    <arm_group_label>Quetiapine and Cannabidiol CR</arm_group_label>
    <arm_group_label>Risperidone and Cannabidiol CR</arm_group_label>
    <other_name>Arvisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <arm_group_label>Amisulpride and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <arm_group_label>Olanzapine and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <arm_group_label>Quetiapine and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <arm_group_label>Risperidone and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cannabidiol CR and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent given by the subject&#xD;
&#xD;
          -  Both, female and male subjects may participate&#xD;
&#xD;
          -  Age between 18 and 45&#xD;
&#xD;
          -  Negative drug screening at the time of screening&#xD;
&#xD;
          -  Non-smoking&#xD;
&#xD;
          -  In female participants in fertile age, reliable contraception, which means&#xD;
             contraception's pearl-index is equal or smaller than 1.&#xD;
&#xD;
          -  Body Mass Index between 18 and 30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of accountability&#xD;
&#xD;
          -  Any current psychiatric disorder through the Structured Clinical Interview for DSM-IV&#xD;
             (SCID) at the time of screening&#xD;
&#xD;
          -  Pregnancy or lactation phase in female at the time of screening&#xD;
&#xD;
          -  Any known psychiatric or neurological illness in the participant's history.&#xD;
&#xD;
          -  Known family history concerning psychiatric disorders&#xD;
&#xD;
          -  Relevant use of cannabis (which is defined on the present state of knowledge as at the&#xD;
             most five times lifetime-consumption and no consumption for at least one year)&#xD;
&#xD;
          -  Severe physical (internal) or neurological illness, especially cardiovascular, renal,&#xD;
             advanced respiratory, haematological or endocrinological failures or infectious&#xD;
             diseases (acute hepatitis A, B or C or HIV) assessed at the time of the screening by&#xD;
             the subject's history, clinical examination and laboratory testing, at the discretion&#xD;
             of the investigator&#xD;
&#xD;
          -  Consumption of any illicit drugs (except cannabis in history, see above)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pharmacology, University of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

